NCT02798744View on ClinicalTrials.gov

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 30, 2019

Study Completion Date

July 30, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

25mg once daily to be taken orally for the duration of the study (24 weeks)

BEHAVIORAL

Diet

Daily energy restriction diet to be followed for the duration of the study (24 weeks)

DRUG

Placebo

Placebo once daily for the duration of the study (24 weeks)

Trial Locations (1)

LE5 4PW

Leicester Diabetes Centre, Leicester

All Listed Sponsors
collaborator

Loughborough University

OTHER

collaborator

University Hospitals, Leicester

OTHER

lead

University of Leicester

OTHER

NCT02798744 - SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. | Biotech Hunter | Biotech Hunter